ABT earnings analysis — 8-K, transcript, guidance雅培 (ABT) 财报解读 — 8-K、电话会、量化指引
Abbott Laboratories (ABT) Q2 2026 Earnings Follow-Up Analysis
1. Actual vs Consensus: Adjusted diluted non-GAAP EPS came in at $1.31, beating the consensus estimate of $1.28 by 2.3%; total revenue hit $12.6B, exceeding the $12.5B consensus by 0.5%, both core metrics outperformed street expectations (source: official earnings release, consensus market data).
2. Revenue Quality & Profitability: Reported revenue grew 13.0% YoY, with comparable sales growth of 4.8%. Gross margin reached 58.0%, operating margin 14.2%, while operating income fell 3.3% YoY; EBIT and EBITDA both stood at $1.8B with matching margins. GAAP diluted EPS was $0.53, net income $928M, with a net margin of 7.4% (source: official earnings release, SEC 8-K filing).
3. Cash Conversion & Capital Position: Quarterly operating cash flow totaled $1.3B, capex $399M, and free cash flow $916M. Ending cash balance was $6.8B, total debt $34.0B, and net debt $27.2B (source: SEC 8-K filing).
4. Guidance: Full-year comparable sales growth guidance was reaffirmed at 6.5% to 7.5%; adjusted non-GAAP EPS guidance was raised to $5.45-$5.60, up from the prior range of $5.38-$5.58 (source: official earnings release, Q2 2026 earnings call transcript).
5. GAAP vs Non-GAAP: The official release clearly disclosed GAAP diluted EPS of $0.53 and adjusted non-GAAP EPS of $1.31, with reconciliation details referenced in regulatory filings (source: official earnings release).
6. Management Commentary: Per the earnings call, Q2 comparable sales growth accelerated from the prior two quarters; Diagnostics saw strong core lab growth, with Cancer Diagnostics boosted by double-digit Cologuard sales; Nutrition saw sequential improvement, with U.S. adult nutrition retail consumption posting double-digit YoY growth; Established Pharmaceuticals grew solidly in emerging markets, with key pipeline updates completed in the quarter.
7. Unresolved Investor Questions: Missing segment-level order/backlog data, full capex deployment details, 10-Q specific metrics, and granular pricing or demand driver breakdowns for individual business units.
雅培实验室(ABT)2026年第二季度财报跟进分析
1. 业绩超预期：第二季度调整后摊薄每股收益(非GAAP)为1.31美元，超出市场一致预期的1.28美元，增幅2.3%；总营收126亿美元，超出市场预期的125亿美元，增幅0.5%，两项核心指标均跑赢市场共识（来源：官方财报发布、市场一致预期数据）。
2. 营收与盈利质量：报告口径营收同比增长13.0%，可比营收增长4.8%。整体毛利率58.0%，营业利润率14.2%，营业利润同比下滑3.3%；EBIT和EBITDA均为18亿美元，利润率持平。GAAP口径摊薄EPS为0.53美元，净利润9.28亿美元，净利润率7.4%（来源：官方财报发布、SEC 8-K文件）。
3. 现金流与资本状况：当期经营性现金流13亿美元，资本支出3.99亿美元，自由现金流9.16亿美元。期末现金余额68亿美元，总债务340亿美元，净债务272亿美元（来源：SEC 8-K文件）。
4. 业绩指引：全年可比营收增长指引维持6.5%-7.5%；调整后EPS指引上调至5.45-5.60美元，此前区间为5.38-5.58美元，为上调指引（来源：官方财报发布、电话会议纪要）。
5. GAAP与非GAAP差异：当期GAAP摊薄EPS为0.53美元，非GAAP调整后EPS为1.31美元，两者差异已在官方文件中明确披露（来源：官方财报发布）。
6. 管理层点评：电话会议显示，第二季度可比营收增速较前两季度加快；诊断部门核心实验室业务增长强劲，癌症诊断业务受Cologuard产品双位数增长推动；营养部门环比改善，美国成人营养零售消费实现双位数同比增长；制药部门新兴市场业务增长稳健。管线方面完成多项关键进展。
7. 未明确事项：缺少各细分板块的订单/预收账款数据、完整资本支出使用明细，未披露10-Q相关细节，部分业务的具体定价策略细节尚未明确。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。